UK markets closed

HYLORIS PHARMA. S.A. (52U.F)

Frankfurt - Frankfurt Delayed price. Currency in EUR
Add to watchlist
13.35+0.15 (+1.14%)
At close: 5:24PM CEST
Full screen
Previous close13.20
Open13.05
Bid0.00 x N/A
Ask0.00 x N/A
Day's range13.05 - 13.35
52-week range9.00 - 14.40
Volume50
Avg. volume27
Market capN/A
Beta (5Y monthly)N/A
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • Globe Newswire

    Hyloris Reports 2021 Half-Year Results: Multiple Potential Value Inflection Points Ahead

    On target to grow the broad product pipeline with at least 3 additional programmes before end 2021Significant expansion of commercial footprint of non-opioid pain treatment Maxigesic® IV Expected to start 2 clinical studies and to report the results from 2 clinical studies before year-end €53.47 million in cash and cash equivalents to execute ambitious growth strategy Conference call and webcast today at 3pm CEST/9am EST (details below) Liège, Belgium – 4 August 2021 – Hyloris Pharmaceuticals SA

  • Globe Newswire

    Hyloris to Report 2021 Half-Year Results on 4 August 2021

    Liège, Belgium – 27 July 2021 – Hyloris Pharmaceuticals SA (Euronext Brussels: HYL), a specialty biopharma company committed to addressing unmet medical needs through reinventing existing medications, today announces that it will host a conference call and audio webcast on Wednesday, 4 August 2021 at 3:00 pm CEST (9:00 am EST) to present its half-year 2021 financial results and to provide a business update. The presentation will be followed by a live Q&A session. The webcast may be accessed on t

  • Globe Newswire

    Hyloris Announces Launch of Maxigesic® IV, a Novel Non-Opioid Pain Treatment, in Key European Markets

    Marks first European launches of Maxigesic IV, a well-tolerated and effective non-opioid pain treatment Liège, Belgium – 8 July 2021 – Hyloris Pharmaceuticals SA (Euronext Brussels: HYL), a specialty biopharma company committed to addressing unmet medical needs through reinventing existing medications, today announces that Maxigesic IV is now available in Germany, the largest European pharmaceutical market, and Austria. Maxigesic IV is a novel, patented, non-opioid treatment for post-operative p